-
1دورية أكاديمية
المصدر: Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 75-80 (2024)
مصطلحات موضوعية: libretto-431, selpercatinib, ret fusion positive nsclc, pralsetinib, immunotherapy in never-smokers, relative dose intensity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
2دورية أكاديمية
المصدر: Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 69-73 (2024)
مصطلحات موضوعية: afatinib, uncommon egfr mutations, g719x, s768i, l861q, achilles, relative dose intensity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
-
3دورية أكاديمية
المؤلفون: Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Jinhang Kim, Chang-Hoon Lee, Ga-Young Song, Deok-Hwan Yang, Jae-Yong Kwak
المصدر: The Korean Journal of Internal Medicine, Vol 39, Iss 3, Pp 501-512 (2024)
مصطلحات موضوعية: diffuse large b-cell lymphoma, simplified geriatric assessment, prognosis, dose intensity, toxicity, Medicine
وصف الملف: electronic resource
العلاقة: http://www.kjim.org/upload/kjim-2023-265.pdfTest; https://doaj.org/toc/1226-3303Test; https://doaj.org/toc/2005-6648Test
-
4دورية أكاديمية
المؤلفون: Po‐Wei Liao, Hsueh‐Ju Lu, Tsung‐Chih Chen, Hsin‐Chen Lin, Yu‐Hsuan Shih, Chieh‐Lin Jerry Teng
المصدر: Cancer Reports, Vol 7, Iss 5, Pp n/a-n/a (2024)
مصطلحات موضوعية: adverse events, constipation, dose intensity, overall survival, progression‐free survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
العلاقة: https://doaj.org/toc/2573-8348Test
-
5دورية أكاديمية
المؤلفون: Rushi Shah, Clarissa Polen-De, Michaela McGree, Angela Fought, Amanika Kumar
المصدر: Current Oncology, Vol 30, Iss 11, Pp 9501-9513 (2023)
مصطلحات موضوعية: sarcopenia, adjuvant chemotherapy, advanced epithelial ovarian cancer, relative dose intensity, cytoreductive surgery, overall survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
العلاقة: https://www.mdpi.com/1718-7729/30/11/688Test; https://doaj.org/toc/1198-0052Test; https://doaj.org/toc/1718-7729Test
-
6دورية أكاديمية
المؤلفون: Tatsuya Yamashita, Natsumi Suzuki, Katsuaki Motoyoshi, Wanjun Zhu, Junji Furuse
مصطلحات موضوعية: Medicine, Pharmacology, Immunology, Cancer, Science Policy, Biological Sciences not elsewhere classified, unresectable hepatocellular carcinoma, prospective cohort study, objective response rate, marketing surveillance study, disease control rate, better performance status, better overall conditions, better modified albumin, adverse drug reactions, relative dose intensity, physician 8217, na 239, treatment group often, median treatment duration, term lenvatinib treatment, longer treatment tended, longer treatment period, lenvatinib dose modifications, initial 177 days, hoc analysis aimed, e ., rdi, two treatment groups, treatment (& lt
-
7دورية أكاديمية
المؤلفون: Tatsuya Yamashita, Natsumi Suzuki, Katsuaki Motoyoshi, Wanjun Zhu, Junji Furuse
مصطلحات موضوعية: Medicine, Pharmacology, Immunology, Cancer, Science Policy, Biological Sciences not elsewhere classified, unresectable hepatocellular carcinoma, prospective cohort study, objective response rate, marketing surveillance study, disease control rate, better performance status, better overall conditions, better modified albumin, adverse drug reactions, relative dose intensity, physician 8217, na 239, treatment group often, median treatment duration, term lenvatinib treatment, longer treatment tended, longer treatment period, lenvatinib dose modifications, initial 177 days, hoc analysis aimed, e ., rdi, two treatment groups, treatment (& lt
-
8دورية أكاديمية
المؤلفون: Tatsuya Yamashita, Natsumi Suzuki, Katsuaki Motoyoshi, Wanjun Zhu, Junji Furuse
مصطلحات موضوعية: Medicine, Pharmacology, Immunology, Cancer, Science Policy, Biological Sciences not elsewhere classified, unresectable hepatocellular carcinoma, prospective cohort study, objective response rate, marketing surveillance study, disease control rate, better performance status, better overall conditions, better modified albumin, adverse drug reactions, relative dose intensity, physician 8217, na 239, treatment group often, median treatment duration, term lenvatinib treatment, longer treatment tended, longer treatment period, lenvatinib dose modifications, initial 177 days, hoc analysis aimed, e ., rdi, two treatment groups, treatment (& lt
-
9دورية أكاديمية
المؤلفون: Tatsuya Yamashita, Natsumi Suzuki, Katsuaki Motoyoshi, Wanjun Zhu, Junji Furuse
مصطلحات موضوعية: Medicine, Pharmacology, Immunology, Cancer, Science Policy, Biological Sciences not elsewhere classified, unresectable hepatocellular carcinoma, prospective cohort study, objective response rate, marketing surveillance study, disease control rate, better performance status, better overall conditions, better modified albumin, adverse drug reactions, relative dose intensity, physician 8217, na 239, treatment group often, median treatment duration, term lenvatinib treatment, longer treatment tended, longer treatment period, lenvatinib dose modifications, initial 177 days, hoc analysis aimed, e ., rdi, two treatment groups, treatment (& lt
-
10دورية أكاديمية
المؤلفون: Melanie Potiaumpai, Erica A. Schleicher, Ming Wang, Kristin L. Campbell, Kathleen Sturgeon, Kathryn H. Schmitz
المصدر: Cancer Medicine, Vol 12, Iss 9, Pp 10715-10724 (2023)
مصطلحات موضوعية: chemotherapy, chemotherapy completion, exercise, exercise oncology, relative dose intensity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
العلاقة: https://doaj.org/toc/2045-7634Test